Pulnovo Medical Announces Strategic Investment from Medtronic in oversubscribed $100 Million Financing Round

Pulnovo Medical, a leader in innovative therapies for pulmonary hypertension and heart failure, has successfully completed an oversubscribed $100 million strategic financing round, primarily led by Medtronic, a prominent global medical technology company. The funding round, announced on April 20, 2026, also saw participation from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, alongside new investor HSG (formerly Sequoia China). This financing is poised to significantly bolster Pulnovo's growth initiatives and enhance its clinical development and international commercialization efforts.

The strategic partnership with Medtronic not only provides substantial financial backing but also opens avenues for future commercialization opportunities. Medtronic's extensive global reach and expertise in medical technology are expected to complement Pulnovo's innovative Pulmonary Artery Denervation (PADN) System. This proprietary system targets the underlying mechanisms of cardiopulmonary disease, demonstrating significant clinical benefits, including improved patient outcomes. With approximately 1,500 PADN procedures performed globally and regulatory approvals secured in seven countries, Pulnovo is well-positioned to expand its footprint in the European Union, Middle East, and China.

The funding will be directed towards ongoing clinical trials and regulatory submissions, as well as enhancing Pulnovo's core technology platform. The company has already received FDA Breakthrough Device designation in the United States and has initiated two fully approved Investigational Device Exemption (IDE) trials. These trials are aimed at further validating the PADN system's efficacy and safety, which is crucial for addressing the unmet needs of patients suffering from heart failure and related conditions.

Pulnovo's strategic growth is further supported by the recent appointment of Andre Xiao as Chief Strategy Officer. His extensive experience in healthcare investment and global capital markets is expected to strengthen Pulnovo's connections with investors and industry partners, facilitating the company's next phase of growth. This leadership transition marks a significant shift from a product-driven approach to a fully integrated global platform, emphasizing the importance of strategic ecosystem partnerships.

The successful fundraising round and strategic collaboration with Medtronic reflect broader trends in the medical technology sector, where innovation and strategic partnerships are increasingly vital for growth. As the demand for advanced therapies for chronic conditions like pulmonary hypertension and heart failure continues to rise, Pulnovo's advancements in clinical development and commercialization are likely to play a crucial role in shaping the future of treatment options in this space. The ongoing evolution of Pulnovo Medical positions it as a key player in addressing significant healthcare challenges, ultimately improving patient outcomes on a global scale.